Lethal multiple sclerosis relapse after natalizumab withdrawal

Neurology. 2012 Nov 27;79(22):2214-6. doi: 10.1212/WNL.0b013e318275979d. Epub 2012 Oct 24.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Drug Therapy, Combination / methods
  • Fatal Outcome
  • Humans
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / immunology
  • Multiple Sclerosis, Relapsing-Remitting / mortality
  • Natalizumab
  • Recurrence
  • Substance Withdrawal Syndrome / diagnosis
  • Substance Withdrawal Syndrome / immunology
  • Substance Withdrawal Syndrome / pathology

Substances

  • Antibodies, Monoclonal, Humanized
  • Natalizumab